HK Stock Market Move | JACOBSON PHARMA (02633) rose nearly 6%, cumulatively up over 60% in the past six months. The mid-term continuous operating profit has grown significantly.

JACOBSON PHARMA (02633) rose nearly 6%, with the stock price increasing by over 60% in the past six months. As of the time of writing, it has risen by 5.83%, reaching 1.09 Hong Kong dollars, with a trading volume of 14.006 million Hong Kong dollars. On the news front, JACOBSON PHARMA recently announced its interim results for the six months ended September 30, 2024. The group's revenue from continuing operations was approximately 810 million Hong Kong dollars, a 13.3% increase year-on-year; its profit from continuing operations was approximately 140.3 million Hong Kong dollars, a 44.2% increase year-on-year; and its earnings per share were 7.07 Hong Kong cents, with a proposed interim dividend of 3.5 Hong Kong cents per share. The company stated that the significant growth in profit from continuing operations during the period was mainly due to the strong performance of its non-patented drug business in both public and private sectors, as well as the revenue contribution from new licensed products and successful launches of new products. Additionally, the company's operational leverage from increased production facilities and cost control measures effectively reducing financial expenses all contributed to the growth.